Agus Turchan

Agus Turchan

Auto-generated profile, based on publicly available information

Agus Turchan

Department of Neurosurgery, Dr.Soetomo General Academic Hospital, Surabaya, Indonesia, Surabaya, Indonesia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
RNRizha Anshori Nasution
Rizha Anshori Nasution
AIAndi Asadul Islam
Andi Asadul Islam
MHMochammad Hatta
Mochammad Hatta
PRPrihantono
Prihantono
ATAgus Turchan
Agus Turchan
MFMuhammad Faruk
Muhammad Faruk
The central nervous system (CNS) is the most metabolically active organ characterized by high oxygen demand and relatively low anti-oxidative activity, which makes neurons and glia highly susceptible to damage by reactive oxygen and nitrogen byproducts as well as neurodegeneration. Free radicals are associated with secondary injuries that occur after a primary brain injury. Some of these free radical products include F2-Isoprostane (F2-IsoPs), malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) and acrolein. In this study we measured serum F2-IsoPs levels as markers of free radical activity in 10–12 week-old male Sprague-Dawley rats weighing 200–300 g, all rats (n = 10) subjected with a head injury according to the modified marmourou model, then divided into 2 groups, one group treated with CAPE (Caffeic Acid Phenethyl Ester) (n = 5) and the other not treated with CAPE (n = 5), serum levels in the two groups were compared starting from day-0 (before brain injury), day-4 and day-7. We found lower F2-IsoPs levels in the group that received the CAPE treatment compared to the group that did not receive the CAPE treatment. CAPE is capable of significantly reducing oxidative stress in brain injury.

31 August 2021 in JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Verified
Journal Article
Open access
FPFinna Permata Putri
Finna Permata Putri
ATAgus Turchan
Agus Turchan
NFNurmawati Fatimah
Nurmawati Fatimah
MYMuhtarum Yusuf
Muhtarum Yusuf
Introduction: Traumatic brain injury (TBI) has a concerning incidence rate. One of the therapies for patients with TBI is non-steroidal anti-inflammatory drugs (NSAID) administration as an analgesic with proper adherence to achieve optimal therapy results. This research aimed to evaluate physicians’ NSAID administration adherence in patients with mild and moderate TBI in Dr. Soetomo General Hospital, Surabaya.Methods: This was an observational descriptive study with a retrospective design. NSAID administration adherence was graded by evaluating the dose, route, frequency, and interval of NSAID administration. The variables were evaluated by observing the medical records of inpatients with mild and moderate TBI from 1 January to 31 December 2018.Results: NSAIDs used for TBI management were metamizole, paracetamol, mefenamic acid, and ketorolac. Metamizole was administered in 10 patients (34.5%), paracetamol in 1 patient (3.4%), metamizole and paracetamol in 15 patients (51.7%), metamizole and mefenamic acid in 1 patient (3.4%), metamizole and paracetamol with mefenamic acid in 1 patient (3.4%), and metamizole and ketorolac in 1 patient (3.4%). Adherence of paracetamol, mefenamic acid, and ketorolac administration in patients with mild and moderate TBI were well-administered in every evaluated variable. Metamizole administration’s adherence was already well-administered in drug dosage and drug administration route, but it was not well-administered in drug administration interval and frequency.Conclusion: Physicians’ adherence to NSAID administration in patients with mild and moderate TBI in Dr. Soetomo General Hospital, Surabaya was well-administered, except for metamizole.

30 March 2024 in Bali Medical Journal
Verified
Journal Article
Open access
PDF file
AIArif Ismail
Arif Ismail
ATAgus Turchan
Agus Turchan
ISI Ketut Sudiana
I Ketut Sudiana
BUBudi Utomo
Budi Utomo
MPMuhammad Arifin Parenrengi
Muhammad Arifin Parenrengi
WSWihasto Suryaningtyas
Wihasto Suryaningtyas
Background: Neuropathic pain remains challenging to treat with pharmacotherapy. One treatment option for neuropathic pain is gabapentin. Interleukin 6 (IL-6) is an inflammatory cytokine that has a vital role in pain. This study aims to determine the effect of oral gabapentin on the pro-inflammatory cytokines interleukin-6 (IL-6) and anti-inflammatory interleukin-10 (IL-10) in the dorsal column of the spinal cord with models of peripheral neuropathic pain. Methods: Twenty-three Rattus norvegicus strain Sprague-Dawley rats with peripheral nerve neuropathic lesion model achieved using a partial sciatic nerve ligation (PSL) procedure. Rats were divided into three groups, namely the normal group (negative control), the PSL group without Gabapentin (positive control), and the PSL group with Gabapentin (treatment). The treatment group was given 50 mg/kg BW/day oral Gabapentin on days 8 to 14. The rats were sacrificed for 15th days. The spinal cord was stained with immunohistochemistry for IL-6 and IL-10 cytokines. The results were analyzed using the SPSS application. Results: The results showed a significant difference in IL-6 expression between groups (p0.05). There was no significant difference in IL-10 expression groups between the treatment group and the positive control group (p>0.05) Conclusion: Oral Gabapentin does not alter the expression of IL-6 and IL-10 in the dorsal horn of the spinal cord following neuropathic lesions of peripheral neurons.

31 July 2022 in AKSONA
Verified
Journal Article
Open access
PDF file
ATAgus Turchan
Agus Turchan
AAAlivery Raihanada Armando
Alivery Raihanada Armando
MAMeisy Andriana
Meisy Andriana
MKMartha Kurnia Kusumawardani
Martha Kurnia Kusumawardani
Highlight: ABSTRACT Introduction: Approximately 90 million traumatic brain injury (TBI) cases worldwide exist yearly. TBI pathophysiology varies, which may cause diverse complications. These complications may decrease the patients’ quality of life. Objective: Describing the quality of life of traumatic brain-injured patients after being treated at Dr. Soetomo General Academic Hospital Period 2018-2020. Methods: This research is a descriptive cross-sectional study using SF-36 questionnaire data from patients with post-severe brain injury at Dr. Soetomo General Academic Hospital in 2018-2020. Results: The value of the physical component (59.9) and mental component (68.6) in patients with severe brain injury at Dr. Soetomo General Academic Hospital showed a good quality of life, with values ​​in the SF-36 domains, namely physical function (58.2), physical limitations (46.7), body pain (73.6), general health (61.3), vitality (65.3), social functioning (72.5), emotional limitations (60), and mental health (76.5) is above the threshold value (50) except for physical limitations (46.7).Conclusion: Patients with severe brain injury had a good quality of life after receiving treatment in Dr. Soetomo General Academic Hospital.

21 February 2025 in Surgical Neurology International
Verified
Journal Article
Open access
AMAkmal Niam Firdausi Masyhudi
Akmal Niam Firdausi Masyhudi
HSHeri Subianto
Heri Subianto
AFAchmad Fahmi
Achmad Fahmi
RSRahadian Indarto Susilo
Rahadian Indarto Susilo
Budi UtomoBudi Utomo
Budi Utomo
ATAgus Turchan
Agus Turchan
Background: Trigeminal neuralgia (TN) is a disease that impairs patients’ daily activities. Microvascular decompression (MVD) is known as the best procedure to relieve pain, yet a small portion of patients still experience pain after surgery. This study will analyze the prognostic factor of MVD for TN patients. Methods: This is a retrospective cohort study of patients with TN who underwent MVD in an Indonesian tertiary hospital from January 2012 to December 2023. It combines medical records and patient interviews followed by statistical analysis to identify prognostic factors influencing the outcome of MVD for TN. Results: Good response to carbamazepine is a favorable factor for short-term pain-free following MVD (P = 0.01). The type of pain emerged as the sole significant prognostic indicator for short-term (P < 0.001) and long-term (P = 0.04) pain relief following MVD. The duration of pain, the type of blood vessels compressing, and the location of compression demonstrated no statistically significant prognostic value on post-MVD pain-free outcomes. Conclusion: MVD outcomes are influenced by several factors, including trigeminal pain type (for short and long-term outcomes) and response to carbamazepine (short-term outcomes). Conversely, other factors thought to influence MVD outcomes, such as the duration of pain, the type of blood vessel compressing the nerve, or the site of nerve compression, have not been proven to influence the procedure’s outcome.

5 October 2026 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
ABAhmad Budirahaji
Ahmad Budirahaji
RSRahadian Indarto Susilo
Rahadian Indarto Susilo
JWJoni Wahyuhadi
Joni Wahyuhadi
RSRiyanarto Sarno
Riyanarto Sarno
AFAchmad Fahmi
Achmad Fahmi
Budi UtomoBudi Utomo
Budi Utomo
Background: Augmented Reality (AR) integrates virtual anatomical information into the real-world environment in real time and has emerged as a promising navigation adjunct in cranial neurosurgery. Compared with conventional neuronavigation (CN), AR Head-Mounted Display (HMD) systems project patient-specific anatomy directly into the surgeon’s field of view, potentially improving spatial perception, ergonomics, and surgical workflow. However, their clinical performance remains uncertain because the available evidence is limited and methodologically heterogeneous. This systematic review synthesizes the accuracy and efficiency of AR HMD in cranial neurosurgical procedures. Methods: A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and ScienceDirect were searched for prospective clinical studies comparing AR HMD with conventional neuronavigation or reporting quantitative accuracy and/or efficiency outcomes in cranial neurosurgery. Results: Nine prospective non-randomized studies involving 186 patients were included. Accuracy was assessed using registration error, deviation error, percent overlap, and subjective or objective evaluations. Among the five studies reporting registration accuracy, registration error ranged from 1.86 to 4.4 mm. Deviation errors were approximately 4 mm, and spatial congruence exceeded 65%. Subjective and objective assessments also demonstrated favorable anatomical localization and lesion visualization. Efficiency outcomes included registration, setup, planning, and navigation time. Registration time ranged from 2.6 to 7.95 min. Among five comparative studies, two reported shorter procedural times with AR HMD, one reported comparable time, and two reported longer times than conventional neuronavigation. Conclusion: AR HMD technology is a promising adjunct for cranial neurosurgical navigation, providing clinically useful accuracy comparable to conventional neuronavigation in selected applications while improving spatial orientation, ergonomics, and surgical workflow. Current systems should be regarded as complementary rather than replacement technologies and appear most suitable for cranial procedures requiring low to moderate precision navigation. Further prospective multicenter studies with standardized validation protocols and continued technological refinement are needed before widespread clinical adoption.